{
    "clinical_study": {
        "@rank": "125886", 
        "acronym": "PILOT", 
        "arm_group": [
            {
                "arm_group_label": "IMAB362 + ZA", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IMAB362 + ZA + IL-2 (1 million IU)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IMAB362 + ZA + IL-2 (3 million IU)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IMAB362", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the trial is to assess the immunological effects and their kinetics, the\n      safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses\n      of Interleukin-2 in subjects with advanced gastroesophageal cancer."
        }, 
        "brief_title": "Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "CLDN18.2-positive Gastric Adenocarcinoma", 
            "CLDN18.2-positive Adenocarcinoma of Esophagus", 
            "CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the stomach, the esophagus or the\n             gastroesophageal junction\n\n          -  Inoperable locally advanced disease, resections with R0, R1 or R2 outcome or\n             metastatic disease.\n\n          -  CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor\n             tissue sample.\n\n          -  Measurable and/or non-measurable disease as defined according to RECIST v1.1\n\n          -  Age \u2265 18 years\n\n          -  Written informed consent\n\n          -  ECOG performance status (PS) 0-1\n\n          -  Life expectancy > 3 months\n\n        Exclusion Criteria:\n\n          -  Prior hypersensitivity reaction or intolerance to one of the compounds of the study\n             treatment\n\n          -  Known HIV infection or known symptomatic hepatitis (A, B, C)\n\n          -  Clinical symptoms of cerebral metastases\n\n          -  Pregnancy or breastfeeding\n\n          -  Patients treated with any bisphosphonate-based therapeutic for any indication during\n             the previous year\n\n          -  Hypocalcemia that requires medication. Corrected (adjusted for serum albumin) serum\n             calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL (3.0 mmol/L)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01671774", 
            "org_study_id": "GM-IMAB-001-04", 
            "secondary_id": "2011-005509-64"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "IMAB362 + ZA", 
                    "IMAB362 + ZA + IL-2 (1 million IU)", 
                    "IMAB362 + ZA + IL-2 (3 million IU)", 
                    "IMAB362"
                ], 
                "description": "800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle", 
                "intervention_name": "IMAB362", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "IMAB362 + ZA", 
                    "IMAB362 + ZA + IL-2 (1 million IU)", 
                    "IMAB362 + ZA + IL-2 (3 million IU)"
                ], 
                "description": "4 mg on d 1 of cycle 1 and cycle 3", 
                "intervention_name": "Zoledronic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IMAB362 + ZA + IL-2 (1 million IU)", 
                "description": "1 million IU on day 1, 2 and 3 of cycles 1 and 3.", 
                "intervention_name": "Interleukin-2 (1 million IU)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "IMAB362 + ZA + IL-2 (3 million IU)", 
                "description": "3 million IU on day 1, 2 and 3 of cycles 1 and 3.", 
                "intervention_name": "Interleukin-2 (3 million IU)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interleukin-2", 
                "Zoledronic acid", 
                "Diphosphonates"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "60488"
                    }, 
                    "name": "Institut f\u00fcr Klinische Forschung, Krankenhaus Nordwest GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Sachsen", 
                        "zip": "01307"
                    }, 
                    "name": "BAG / Onkologische Schwerpunktpraxis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Charit\u00e9 Universit\u00e4tsmedizin Berlin - CVK, Med. Klinik m.S. H\u00e4matologie und Onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Freiburg University Medical Center, Department of Internal Medicine II, Gastroenterology and Hepatology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04109"
                    }, 
                    "name": "Leipzig University Hospital, University Cancer Center (UCCL)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "72076"
                    }, 
                    "name": "University Hospital Tuebingen, Department of Internal Medicine I - Gastroenterology, Hepatology, Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89070"
                    }, 
                    "name": "Ulm University Hospital, Center for Internal Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liepaja", 
                        "country": "Latvia", 
                        "zip": "3401"
                    }, 
                    "name": "Piejuras Hospital, Oncology Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riga", 
                        "country": "Latvia", 
                        "zip": "LV1038"
                    }, 
                    "name": "Riga East University Hospital, LLC, Latvian Oncology Center"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Czech Republic", 
                "Germany", 
                "Latvia"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus or the Gastro-esophageal Junction.", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Descriptive statistics for treatments will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped.", 
                "measure": "Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "at least 18 months"
            }, 
            {
                "description": "Descriptive statistics for treatments will be given on the number and activity of immune cells in peripheral blood of patients.", 
                "measure": "Immune cell profile and kinetics", 
                "safety_issue": "No", 
                "time_frame": "at least 18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01671774"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS is defined as the time from registration of therapy to the first observation of disease progression or death from any cause or last tumor evaluation if free of progression. For patients who have not progressed either clinically or on the last scan, they will be censured as of the last tumor evaluation.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "at least 18 months"
            }, 
            {
                "description": "ORR comprises the fraction of patients with CR, PR according to RECIST v1.1. It is set in relation to the ITT population and PP population.", 
                "measure": "Objective tumor response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "at least 18 months"
            }, 
            {
                "description": "DCR is defined as the fraction of patients with CR or PR or SD according to RECIST v1.1. It is set in relation to the ITT population and PP population.", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "at least 18 months"
            }, 
            {
                "description": "Duration of response is determined as the time when criteria for CR, PR, and SD are first met until the first date that recurrent or progressive disease or death occurs.", 
                "measure": "Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "at least 18 months"
            }
        ], 
        "source": "Ganymed Pharmaceuticals AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ganymed Pharmaceuticals AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}